Raymond James & Associates grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,393 shares of the company’s stock after acquiring an additional 1,109 shares during the period. Raymond James & Associates’ holdings in Neurocrine Biosciences were worth $1,021,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Tocqueville Asset Management L.P. raised its position in Neurocrine Biosciences by 8.5% during the second quarter. Tocqueville Asset Management L.P. now owns 19,075 shares of the company’s stock worth $1,874,000 after acquiring an additional 1,500 shares during the last quarter. OppenheimerFunds Inc. grew its holdings in shares of Neurocrine Biosciences by 2.0% during the second quarter. OppenheimerFunds Inc. now owns 851,453 shares of the company’s stock worth $83,647,000 after buying an additional 16,455 shares in the last quarter. Van ECK Associates Corp grew its holdings in shares of Neurocrine Biosciences by 18.5% during the second quarter. Van ECK Associates Corp now owns 123,542 shares of the company’s stock worth $12,137,000 after buying an additional 19,302 shares in the last quarter. Gould Asset Management LLC CA purchased a new stake in shares of Neurocrine Biosciences during the second quarter worth about $236,000. Finally, International Biotechnology Trust PLC grew its holdings in shares of Neurocrine Biosciences by 6.2% during the second quarter. International Biotechnology Trust PLC now owns 163,500 shares of the company’s stock worth $16,061,000 after buying an additional 9,500 shares in the last quarter.
NBIX has been the subject of a number of recent research reports. Needham & Company LLC set a $125.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, August 1st. HC Wainwright reiterated a “buy” rating and set a $162.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, August 1st. Oppenheimer set a $128.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, July 31st. Jefferies Financial Group lifted their price target on shares of Neurocrine Biosciences to $124.00 and gave the stock a “buy” rating in a report on Monday, July 30th. Finally, BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Friday, July 27th. One analyst has rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $122.22.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, July 31st. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. Neurocrine Biosciences had a negative net margin of 16.07% and a negative return on equity of 14.22%. The business had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $84.11 million. During the same period in the previous year, the company posted ($0.68) earnings per share. The business’s revenue for the quarter was up 1428.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 0.15 earnings per share for the current year.
In other news, insider Dimitri E. Grigoriadis sold 23,022 shares of the business’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $110.00, for a total transaction of $2,532,420.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.30% of the company’s stock.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Read More: S&P 500 Index
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.